GSK Plc ADR (GSK) concluded trading on Thursday at a closing price of $36.96, with 6.24 million shares of worth about $230.7 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -10.98% during that period and on February 20, 2025 the price saw a gain of about 1.15%. Currently the company’s common shares owned by public are about 2.04B shares, out of which, 2.04B shares are available for trading.
Stock saw a price change of 2.30% in past 5 days and over the past one month there was a price change of 9.41%. Year-to-date (YTD), GSK shares are showing a performance of 9.28% which decreased to -11.87% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $31.72 but also hit the highest price of $45.92 during that period. The average intraday trading volume for GSK Plc ADR shares is 4.40 million. The stock is currently trading 3.24% above its 20-day simple moving average (SMA20), while that difference is up 6.79% for SMA50 and it goes to -4.47% lower than SMA200.
GSK Plc ADR (NYSE: GSK) currently have 2.04B outstanding shares and institutions hold larger chunk of about 16.79% of that.
The stock has a current market capitalization of $75.43B and its 3Y-monthly beta is at 0.60. PE ratio of stock for trailing 12 months is 23.36, while it has posted earnings per share of $1.58 in the same period. Its PEG reads 3.01 and has Quick Ratio of 0.52 while making debt-to-equity ratio of 1.24. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for GSK, volatility over the week remained 1.29% while standing at 1.60% over the month.
Stock’s fiscal year EPS is expected to rise by 4.80% while it is estimated to increase by 11.26% in next year. EPS is likely to grow at an annualized rate of 7.76% for next 5-years, compared to annual growth of -11.63% made by the stock over the past 5-years.
Stock get a Neutral rating from UBS on July 08, 2024.
